Intellia Therapeutics (NTLA) Misses Q3 EPS by 13c; Cash and Cash Equivalents of $1.15B

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.97), $0.13 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $8.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c